Asthma Therapeutics Market by Product, Drug Class, Route of administration

List of Tables

The Asthma Therapeutics Market was valued at USD 24.70 billion in 2023, expected to reach USD 27.26 billion in 2024, and is projected to grow at a CAGR of 10.63%, to USD 50.10 billion by 2030.

The asthma therapeutics market encompasses a wide array of products and treatments aimed at alleviating symptoms and managing asthma, a chronic respiratory condition affecting millions globally. The necessity for effective asthma therapeutics is underscored by the rising prevalence of asthma, attributable to factors such as urbanization, pollution, and genetic susceptibility. The application of these therapeutics spans from quick-relief medications, like bronchodilators, to long-term control agents, including inhaled corticosteroids and biologics, tailored to various grades of asthma severity. End-use scope primarily includes hospitals, clinics, and homecare settings, where patients either receive or self-administer treatment.

KEY MARKET STATISTICS
Base Year [2023]	USD 24.70 billion
Estimated Year [2024]	USD 27.26 billion
Forecast Year [2030]	USD 50.10 billion
CAGR (%)	10.63%

Key growth influencers in the market include an increase in environmental allergens, technological advancements in drug delivery systems (like smart inhalers), and an expanding geriatric population who are more prone to respiratory ailments. Emerging opportunities lie in personalized medicine, with research focusing on genomic and phenotypic profiling leading to tailored therapeutic strategies. The expanding biopharmaceutical sector also presents lucrative avenues through the development of novel biologics. Companies should leverage partnerships with tech firms to develop intelligent monitoring systems and improve patient adherence, tapping into the potential of telemedicine.

However, market growth is hindered by challenges such as high treatment costs, potential side effects of long-term asthma medication use, and inconsistent medical adherence. Furthermore, regulatory constraints and a slow pipeline for new drug approvals add to market challenges. To ensure business growth, companies should focus on developing affordable generics, invest in R&D for innovative drug formulations, and enhance educational programs to raise awareness of asthma management.

The asthma therapeutics market is dynamic, requiring continuous innovation to adapt to evolving healthcare needs. By addressing high costs and emphasizing patient education, businesses can significantly impact patient outcomes and capitalise on growth opportunities. With precision medicine leading the way, the market is poised for significant advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Asthma Therapeutics Market

The Asthma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Growing Incidences of Asthma and Other Respiratory Diseases
- Recent Improvements in Allergy Detection and Diagnostic Technologies
- Extensive Demand for Monoclonal Antibodies
Market Restraints
- Limitation and Side Effects of Asthma Therapeutic Devices
Market Opportunities
- Development of Combination Therapeutics for The Treatment
- Extensive Research and Development (R&D) Efforts for Asthma Treatment
Market Challenges
- Limited Therapeutics Reach in Remote & Rural Areas

Porter's Five Forces: A Strategic Tool for Navigating the Asthma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Asthma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Asthma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Asthma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Asthma Therapeutics Market

A detailed market share analysis in the Asthma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Asthma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Asthma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Genentech, Inc., Pfizer Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Boston Scientific Corporation, Sunovion Pharmaceuticals, Inc., Medtronic PLC, Softhale NV by invoX Pharma Limited, Koninklijke Philips N.V., Wellinks, Inc., Viatris Inc., Amgen Inc., Sanofi S.A., Biogen Inc., AstraZeneca PLC, Merck & Co, Inc., Parekhplast India Limited, GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Sun Pharmaceutical Industries Limited, Abbott Laboratories, Shenzhen Aeon Technology Co., Ltd., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Lupin Limited, Trudell Medical Limited, Cipla Limited, Merxin Ltd., Novartis AG, and Regeneron Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Inhalers and Nebulizers. The Inhalers is further studied across Dry Powder Inhalers, Metered-Dose Inhalers, and Soft Mist Inhalers.
Based on Drug Class, market is studied across Anti-Inflammatory, Bronchodilators, and Combination Therapy.
Based on Route of administration, market is studied across Inhaled and Oral.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-AB49FC1AB810

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing Incidences of Asthma and Other Respiratory Diseases
  - 5.1.1.2. Recent Improvements in Allergy Detection and Diagnostic Technologies
  - 5.1.1.3. Extensive Demand for Monoclonal Antibodies
- 5.1.2. Restraints
  - 5.1.2.1. Limitation and Side Effects of Asthma Therapeutic Devices
- 5.1.3. Opportunities
  - 5.1.3.1. Development of Combination Therapeutics for The Treatment
  - 5.1.3.2. Extensive Research and Development (R&D) Efforts for Asthma Treatment
- 5.1.4. Challenges
  - 5.1.4.1. Limited Therapeutics Reach in Remote & Rural Areas
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising demand for metered dose inhalers for the treatment of asthma
- 5.2.2. Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
- 5.2.3. Route of administration: Expanding adoption of inhaled asthma medication for fast relief
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
5.5. Client Customization

6. Asthma Therapeutics Market, by Product

6.1. Introduction
6.2. Inhalers
- 6.2.1. Dry Powder Inhalers
- 6.2.2. Metered-Dose Inhalers
- 6.2.3. Soft Mist Inhalers
6.3. Nebulizers

7. Asthma Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Anti-Inflammatory
7.3. Bronchodilators
7.4. Combination Therapy

8. Asthma Therapeutics Market, by Route of administration

8.1. Introduction
8.2. Inhaled
8.3. Oral

9. Americas Asthma Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Asthma Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Asthma Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
- 12.3.2. Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
- 12.3.3. Lupin Launches Luforbec(R) 100/6 for Adult Asthma and COPD Treatment

Companies Mentioned

1. Genentech, Inc.
2. Pfizer Inc.
3. Takeda Pharmaceutical Company
4. Teva Pharmaceutical Industries Ltd.
5. Chiesi Farmaceutici S.p.A.
6. Boston Scientific Corporation
7. Sunovion Pharmaceuticals, Inc.
8. Medtronic PLC
9. Softhale NV by invoX Pharma Limited
10. Koninklijke Philips N.V.
11. Wellinks, Inc.
12. Viatris Inc.
13. Amgen Inc.
14. Sanofi S.A.
15. Biogen Inc.
16. AstraZeneca PLC
17. Merck & Co, Inc.
18. Parekhplast India Limited
19. GlaxoSmithKline PLC
20. Kare Medical and Analytical Devices Ltd. Co.
21. Sun Pharmaceutical Industries Limited
22. Abbott Laboratories
23. Shenzhen Aeon Technology Co., Ltd.
24. Boehringer Ingelheim GmbH
25. F. Hoffmann-La Roche Ltd
26. Lupin Limited
27. Trudell Medical Limited
28. Cipla Limited
29. Merxin Ltd.
30. Novartis AG
31. Regeneron Pharmaceuticals, Inc.